繁體
简体中文
繁體中文

FTI諮詢 FCN

已收盤 12-12 16:00:00 美东时间

170.72

+2.390

+1.42%

华盛通華盛通
立即下載
  • 最 高171.17
  • 今 開169.54
  • 成交量 26.55万股
  • 最 低 167.475
  • 昨 收 168.33
  • 總市值 52.71亿
  • 52周最高 204.69
  • 市盈率 21.85
  • 換手率 0.86%
  • 52周最低 149.31
  • 委 比 21.95%
  • 總股本 3087.61万
  • 歷史最高 243.60
  • 量 比 0.79
  • 振 幅 2.20%
  • 歷史最低 22.88
  • 每 手 1
  • 風險率 12.06%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • FTI Consulting Extends CEO Contract Amid Leadership Changes

    FTI Consulting ( ($FCN) ) has shared an update. On December 8, 2025, FTI Consul...

    12-10 05:50

  • FTI Consulting Appoints Jason Leow to Strategic Communications Segment in Singapore

    FTI Consulting appoints Jason Leow as Senior Managing Director in its Strategic Communications segment. Based in Singapore, Leow brings over 25 years of experience in financial communications and stakeholder engagement across Asia, Europe, and the U.S. His role involves driving growth in Southeast Asia, strengthening the firm's international network, and advancing data-driven strategies. Leow specializes in M&A, ESG, shareholder activism, and cri...

    12-04 00:00

  • Marex Group plc completes acquisition of Winterflood and announces agreement to sell Winterflood’s custody business

    Marex Group plc has acquired Winterflood Securities, enhancing its UK cash equities business, while planning to sell Winterflood Business Services (WBS) to Epiris Fund III. Marex will retain Winterflood's market making activities and brand, with WBS transferred to Epiris upon regulatory approval. The retained Winterflood business expects $75m annual revenue and a 20% profit margin. Ian Lowitt, Marex's CEO, highlighted the sale of WBS offsetting a...

    12-01 12:00

  • FTI Consulting Signs New London Office Lease Agreement

    The latest announcement is out from FTI Consulting ( ($FCN) ). On November 21, ...

    11-27 05:59

  • Diversified Energy Completes Canvas Energy Acquisition

    Diversified Energy completes the acquisition of Canvas Energy for ~$550 million, adding ~147 MMcfepd production and 1.6 million net acres in Oklahoma. The deal includes $400 million ABS financing and issuance of 3.7 million shares. The transaction is expected to generate significant synergies and enhance operational efficiency.

    11-24 15:30

  • Final Approval of The Scheme of Arrangement

    Diversified Energy Company is restructuring to become a Delaware-incorporated company, with the NYSE as its primary listing and retaining a secondary listing on the LSE. The scheme was approved by the High Court, and the changes will take effect on November 24, 2025. The company will continue its share buyback program as previously announced.

    11-21 15:30

  • Publication of a Prospectus

    Diversified Energy Company has announced the approval of its prospectus by the FCA for the listing of its ordinary shares on the London Stock Exchange. The prospectus is available on the company's website and via the National Storage Mechanism. The scheme is expected to become effective on November 21, 2025, with shares listing on the NYSE and LSE on November 24, 2025. For more details, visit the Investor Relations section or contact the listed r...

    11-19 12:41

  • EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

    EyePoint Pharmaceuticals announced that the Data Safety Monitoring Committee (DSMC) recommended continuing its Phase 3 LUGANO and LUCIA trials for DURAVYU as planned, with no protocol changes needed. The safety data remains consistent with prior trials, showing no safety signals. All patients have received their initial dose, and 25% have received their second dose. DURAVYU is being evaluated for wet age-related macular degeneration (wet AMD), wi...

    11-19 12:00

  • Best AI productivity beneficiary stocks - Goldman

    Goldman Sachs has identified a new group of “AI productivity beneficiaries,” highlighting companies best positioned to see earnings lift from automation-driven efficiency gains. Strategist David Kosti...

    11-18 21:52

  • EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    EyePoint Pharmaceuticals granted 7 new employees non-statutory stock options to purchase up to 31,000 shares under NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $11.58, vest over four years and have a 10-year term. EyePoint focuses on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU in Phase 3 trials for wet AMD and DME.

    11-17 12:00